Follow-The-Filings

Security · featured owners

ENTA Enanta Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 15.9%
  • $79M
  • 1 reduce

ENTA (Enanta Pharmaceuticals Inc.) is held in 3 featured 13F books as of 2026 Q2. Michael Krensavage - Krensavage Asset Management is the largest tracked holder by portfolio weight (15.9%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 15.9% (Michael Krensavage - Krensavage Asset Management) · not free-float ownership

  1. Michael Krensavage 15.9%
  2. James Silverman 0.17%
  3. Farallon Capital Management Reduce 0.16%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Michael Krensavage - Krensavage Asset Management 2026 Q2 15.9% Hold 2,866,138 $42M History
Farallon Capital Management 2026 Q2 0.16% Reduce −15.8% 2,418,202 $35M History
James Silverman - Opaleye Management 2026 Q2 0.17% Hold 125,000 $2M History

3 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 13 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 5 rows shown

Filed Form Detail Links
4 Period Aug 8, 2026 Filing Doc
4 Period Mar 11, 2026 · 6 forms Filing Doc
4 Period Feb 12, 2026 · 6 forms Filing Doc
4 Period Dec 5, 2025 · 7 forms Filing Doc
4 Period Dec 1, 2025 · 5 forms Filing Doc

Updated 7 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $79.2M $67.64M $65.32M
Net income -$133.82M -$116.04M -$81.89M
Net margin * -169.0% -171.6% -125.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $422.79M $299.85M $204.34M
Total non-current assets * $39.48M $76.8M $76.4M
Total assets $462.28M $376.65M $280.73M
Total current liabilities $62.79M $57.54M $48.56M
Total non-current liabilities * $182.75M $190.3M $167.46M
Total equity $216.74M $128.81M $64.72M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$103.15M -$78.76M -$19.27M
Cash from investing -$53.58M $58.24M $40.35M
Cash from financing $198.13M -$27.63M -$26.62M
Net change in cash $41.39M -$48.16M -$5.54M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders